4//SEC Filing
Francomano Robert 4
Accession 0001104659-20-022139
CIK 0001264587other
Filed
Feb 13, 7:00 PM ET
Accepted
Feb 14, 9:29 PM ET
Size
7.6 KB
Accession
0001104659-20-022139
Insider Transaction Report
Form 4
Francomano Robert
Chief Commercial Officer
Transactions
- Sale
Common Stock
2020-02-07$6.72/sh−5,064$34,030→ 93,257 total - Award
Common Stock
2020-02-10+105,939→ 199,196 total
Footnotes (5)
- [F1]In connection with the vesting of 12,388 shares on February 6, 2020 a total of 5,064 shares were sold by the Company on February 7, 2020 in order to satisfy the reporting person's tax witholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies.
- [F2]Reflects the weighted average sale price. The range of prices for the shares sold was $6.66 to $6.81. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]Of the shares listed, 43,617 shares are restricted stock.
- [F4]The 105,939 restricted shares will vest in three installments as follows: 35,313 shares on February 24, 2021; 35,313 shares on April 6, 2022; and 35,313 shares on January 25, 2023.
- [F5]Of the shares listed, 149,556 shares are restricted stock.
Documents
Issuer
STEMLINE THERAPEUTICS INC
CIK 0001264587
Entity typeother
Related Parties
1- filerCIK 0001797467
Filing Metadata
- Form type
- 4
- Filed
- Feb 13, 7:00 PM ET
- Accepted
- Feb 14, 9:29 PM ET
- Size
- 7.6 KB